Pro-Dex Inc (PDEX) FinancialsPDEXFinancialPro-Dex Inc

Pro-Dex Inc (PDEX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medical devices, accounting for 81.4% of total sales, equivalent to $16.24M. Other significant revenue streams include Repairs and NRE & Prototypes. Understanding this composition is critical for investors evaluating how PDEX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Pro-Dex Inc maintains a gross margin of 30.74%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 15.51%, while the net margin is 19.74%. These profitability ratios, combined with a Return on Equity (ROE) of 29.83%, provide a clear picture of how effectively PDEX converts its operational activities into shareholder value.

In the context of the broader market, PDEX competes directly with industry leaders such as LUCD and INCR. With a market capitalization of $213.98M, it holds a leading position in the sector. When comparing efficiency, PDEX's gross margin of 30.74% stands against LUCD's -5.16% and INCR's 30.47%. Such benchmarking helps identify whether Pro-Dex Inc is trading at a premium or discount relative to its financial performance.

Pro-Dex has shown strong revenue growth, with Q3 2026 revenue at $19.94 million, up from $18.66 million in Q2 2026. Gross margin remains stable around 30%, and net income for Q3 2026 is $3.94 million, reflecting solid profitability.